A new law to protect workers from needlestick injury is being implemented, but many trusts misunderstand which needles pose the greatest risk.
EU legislation to reduce needlestick injury and consequent infections will come into force in May 2013. The law will oblige healthcare organisations to take measures to prevent needlestick injuries to staff, and strongly recommends the use of safety-engineered medical devices.
Some healthcare organisations have already converted to using safety devices, recognising the need to improve staff safety, reduce the cost of treating injured workers, and avoid expensive legal actions.
The main focus of the directive seems to be on safety-engineered devices for blood collection and infusion, as healthcare organisations often ignore or see the risk of injections into tissue as minimal. There is still a need for further education on the risks of injection.
This article reviews a number of commonly held views regarding the risk of needlestick injury and discusses whether the statements are supported by the evidence.
Citation: Risk of needlestick injury from injecting needles. Nursing Times [online]; 108: 40, 12-16
Author: Kenneth Strauss is endocrinologist and director of safety in medicine, European Medical Association, and global medical director, Becton Dickinson.
- This article has been double-blind peer reviewed
- Scroll down to read the article or download a print-friendly PDF including any tables and figures
Needlestick injuries (NSIs) are one of the most frequent occupational hazards faced by nurses, phlebotomists, doctors and other healthcare workers, as well as those working in cleaning and waste disposal. Such injuries are particularly dangerous in view of their potential for transmitting life-threatening bloodborne pathogens, including hepatitis B (HBV), hepatitis C (HCV) and HIV (European Parliament, 2010). Many of these incidents, for various reasons, never get reported.
HBV transmission requires only 1/10,000ml of infected plasma (Wittman et al, 2009), and many times this amount is resent within the barrel or on the sides of medical sharps, even in devices not used expressly to draw blood or gain vascular access.
A surprising number of NSIs occur after use, during disposal. HBV is stable in dried blood for at least seven days and HCV for at least 16 hours (Centers for Disease Prevention and Control, 1995). Not all healthcare workers are vaccinated against HBV; the European range is 30-90% depending on the country and branch of medicine (Vos et al, 2006).
Legislation to protect healthcare workers
Much work has been done since the millennium by healthcare worker associations to highlight the danger of NSIs. These injuries have been described by the European Parliament as “one of the most serious health and safety threats in European workplaces… estimated to cause one million injuries each year” (EU Commission for Employment, Social Affairs and Inclusion, 2010).
The 2010 EU directive on sharps injury prevention (Council of the EU, 2010) will become law in all EU countries by May 2013, and oblige healthcare organisations to take measures to prevent NSIs to their staff. One measure is the use of safety-engineered medical devices (SEMDs); these are needles, phlebotomy devices and intravenous catheters that incorporate shielding or retraction of the needle.
Safety-engineered medical devices
NSI costs can be substantial when treatment, lost working time and staff turnover are taken into account. A number of organisations have introduced full or partial safety-device policies on the basis of a measured business case. However, this is not the only driving force for safety device conversion. The threat of potentially damaging legal cases, costly compensation claims and adverse publicity, all of which divert attention away from core objectives of delivering high-quality healthcare, may sometimes be the trigger.
There is an established perceived risk of NSI with devices that have been in a vein, whether to draw blood or to infuse medication, so many healthcare organisations are focusing on these devices when taking steps to reduce NSIs.
Although there is a definite risk, it is a common misconception that most NSIs occur with devices that have been in a vein.The device most commonly associated with NSI is an injecting needle. These needles are used frequently to give medications (such as insulin or antibiotics), to aspirate fluids (such as from abscesses) or to reconstitute drugs (for example, chemotherapeutic agents).
Many studies and surveys have placed the common injecting syringe at the top of the frequency table of NSI. In the UK, for example, syringe needles cause more than 25% of NSIs (Watterson, 2005). An overview of epidemiological data from several countries indicates that injection procedures contribute on average to 21% of NSIs (Valls et al, 2007; Bi et al, 2006; Cullen et al, 2006; Watterson, 2005; Perry et al, 2004; PHASE study group, 2001; 2003) Injection procedures are therefore an important cause of exposure of healthcare workers to biological and chemical hazards.
Risks posed by injections
Global conversion to safety-engineered IV catheters and safety-engineered phlebotomy sets has been faster than conversion to safety-engineered injection devices (Jagger et al, 2008), even though the last cause more NSIs.
In the US, where the use of safety devices has been mandatory since 2000, the percentage conversion has lagged behind (year on year) for disposable syringes. There is a lack of perception of the danger of injection-related NSIs, as hospital administrators and staff seem to believe that needles that have been inside veins are riskier than injection devices.
It is a common view that devices that have been in veins are more likely to transmit bloodborne pathogens than those that have gone into other tissues, such as muscle or fat. However, while exposure to blood is a risk factor, there are factors with even higher risks.
Table 1 shows the odds ratio of HIV seroconversion as a function of certain factors (Centers for Disease Control and Prevention, 1995). An odds ratio of 1 implies that the event is equally likely in both groups, and an odds ratio of 16 means that a deep injury is 16 times more likely to transmit HIV than a non-deep injury. The depth of the injury is the most important risk factor. Table 1 shows that sustaining a deep injury carries around three times the risk for transmitting HIV than the presence of visible blood on the needle, the needle having been inside a vessel or the HIV positive patient later dying.
Another study showed similar results regarding HCV conversion (Yazdanpanah et al, 2005). Hypodermic needles have the greatest potential for delivering deep injuries. This is because, for both IV catheters and safety-engineered phlebotomy, the needle is inserted at a shallow angle with the intention of entering a superficial vein, while IM injections are given at 90° with the intention to reach as deep into the muscle as possible without going too deep and into bone or organs.
Contamination of injecting devices
Studies conducted in the US and Italy (PHASE Study Group, 2001; 2003), before safety-engineered devices were introduced, found that approximately one in six hypodermic syringes and needles were contaminated with blood (Table 2). The risk of NSIs from blood-contaminated hypodermic needles is comparable with the risk from IV catheters.
It is often impossible to tell, simply by looking, which hypodermic device is contaminated and which is not. Not seeing blood can lure healthcare practitioners into a false sense of security about NSI with injecting devices.
The average volume of blood inoculated in an associated injury via a 22-gauge needle is approximately 1.0μl and it only takes minute quantities of blood to transmit viruses (Wittman et al, 2009). Table 3 shows the volumes of blood that are required to transmit HIV, HCV and HBV; this much blood is frequently present in used hypodermic needles, and is often not visible to the naked eye.
Reducing needlestick injuries
No intervention can reduce NSI risk to zero, but safety-engineered devices reduce the risk consistently and significantly. A huge range of independent studies conducted in Europe and elsewhere in the world show that a combination of training, safer working practices and the use of medical devices incorporating safety-engineered protection mechanisms can prevent more than 80% of needlestick injuries (De Raeve, 2010).
One prospective study from the University Hospital of Birmingham (Adams and Elliott, 2006) found that after safety-engineered devices had been introduced alongside training, NSI rates fell from 20 per 100,000 procedures to six per 100,000. This study also showed that training and education alone can achieve a modest NSI reduction but this reduction is not sustained in the absence of safety-engineered devices. Significant and sustained NSI reduction came only when safety-engineered products had been added to enhanced education.
Further studies showing similar results have been published from France (Lamontagne et al, 2007), Spain (Valls et al, 2007) and the US (Jagger et al, 2008).
When considering converting to safety-engineered medical devices, many purchasing departments take into account only the additional percentage in costs, whereas the use of a safety device is an investment for the institution as a whole.
In a recent study in Belgium, health economist David Larmuseau has shown that a conversion to safety-engineered devices saves nearly half a million euros per year (Larmuseau, 2007).
Healthcare organisations that have converted recognise that adopting safety-engineered medical devices is fundamental to a safer working environment, to eliminate the cost of treatment and staff absence, and to avoid damaging and expensive legal action.
In contrast to common belief, the risk of NSIs from injecting needles is greater than other activities, such as blood drawing and cannulation.
Now that the EU directive is being implemented, conversion to safety-engineered devices is swiftly becoming a more urgent consideration, as healthcare organisations will be obliged to take preventive and protective measures in all situations where there is a significant risk of sharps injury and infection.
Hospitals and other healthcare organisations will need to build strategies so they comply with the directive, and not to wait for the May 2013 deadline. These strategies should definitely include measures to protect healthcare workers when carrying out medical injections.
- The 2010 EU directive on sharps injury prevention will come into force in May 2013
- There is a business case for reducing needlestick injuries (NSIs) in terms of improving worker safety, reducing the cost of treating injured staff and avoiding costly legal actions
- Organisations tend to focus on safety-engineered devices for blood collection and infusion, rather than medical injections
- Nurses need to be educated on NSI risks associated with injecting into tissue
- The device most commonly associated with NSI is the injecting needle
Adams D, Elliott TS (2006) Impact of safety needle devices on occupationally acquired needlestick injuries: a four-year prospective study. Journal of Hospital Infection; 64: 50-55.
Bi P et al (2006) Occupational blood and body fluid exposure in an Australian teaching hospital. Epidemiology and Infection; 134: 3, 465-471.
Centers for Disease Prevention and Control (1995) Case-control study of HIV seroconversion in health-care workers after percutaneous exposure to HIV Infected blood - France, United Kingdom, and United States January 1988-August 1994. Morbidity and Mortality Weekly Report; 44: 50, 929-933.
Council of the EU (2010) Council directive 2010/32/EU. Implementing the framework agreement on prevention from sharp injuries in the hospital and healthcare sector concluded by HOSPEEM and EPSU Official Journal of the European Union; L134/66-72.
Cullen BL et al (2006) Potential for reported needlestick injury prevention among healthcare workers thorough safety device usage and improvement of guideline adherence: expert panel assessment. Journal of Hospital Infection; 63, 445-451.
De Raeve P (2010) Sharps Injuries - Stepping up to the Challenge in Europe. Brussels: European Federation of Nurses Associations.
EU Commission for Employment, Social Affairs and Inclusion (2010) New Legislation to Reduce Injuries for 3.5 Million Healthcare Workers in Europe. Press Release.
European Parliament (2010) Preventing Needle-Stick Injuries in the Health Sector. Brussels: European Parliament.
Jagger J et al (2008) The impact of US policies to protect healthcare workers from bloodborne pathogens: the critical role of safety-engineered devices. Journal of Infection and Public Health; 1: 62-71.
Lamontagne F et al (2007) Role of safety-engineered devices in preventing needlestick injuries in 32 French hospitals. Infection Control And Hospital Epidemiology; 28: 18-23.
Larmuseau D (2007) Safety Products For Everyone’s (Financial) Benefit (Les Produits de Sécurité, un Avantage (Financier) Pour Tous). Study sponsored by UNAMEC, The Belgian Association for producers and/or distributors of medical devices.
Perry J et al (2007) EPINet report: 2004 percutaneous injury rate. International Healthcare Worker Safety Center; August 2007.
PHASE Study Group (2001; 2003) Rischio biologico e punture accidentali negli operatori sanitari. Series Lauri Edizioni; Milan.
Valls V et al (2007) Use of safety devices and the prevention of percutaneous injuries among healthcare workers. Infection Control Hospital Epidemiology; 28: 12, 1352-1360.
Vos D et al (2006) Needlestick injury and accidental exposure to blood: the need for improving the hepatitis B vaccination grade among health care workers outside the hospital. American Journal of Infection Control; 34: 610-2.
Watterson L (2005) Sharp thinking. Nursing Standard; 20: 5, 20-22.
Wittmann A at al (2009). Übertragene Blutvolumina nach Nadelstichverletzungen an s.c. Kanülen. Dokumentations-CD-ROM über 49. Jahrestagung der DGAUM. 382-384.
Yazdanpanah Y et al (2005) Risk factors for hepatitis C virus transmission to health care workers after occupational exposure: a European case-control study. Clinical Infectious Diseases; 41: 1423-1430.